ARCH Stock Overview
Engages in the development of novel drugs for acute kidney injury and organ damage in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arch Biopartners Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.90 |
| 52 Week High | US$2.56 |
| 52 Week Low | US$1.36 |
| Beta | 1.38 |
| 1 Month Change | 0% |
| 3 Month Change | -2.56% |
| 1 Year Change | 25.00% |
| 3 Year Change | -43.28% |
| 5 Year Change | 123.53% |
| Change since IPO | 400.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARCH | CA Life Sciences | CA Market | |
|---|---|---|---|
| 7D | 1.1% | 0.9% | -0.5% |
| 1Y | 25.0% | -14.6% | 16.2% |
Return vs Industry: ARCH exceeded the Canadian Life Sciences industry which returned -14.6% over the past year.
Return vs Market: ARCH exceeded the Canadian Market which returned 16.2% over the past year.
Price Volatility
| ARCH volatility | |
|---|---|
| ARCH Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 8.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ARCH has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: ARCH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Richard Muruve | www.archbiopartners.com |
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops AB569 for treating antibiotic-resistant bacterial infections and as a topical treatment for wounds; and Borg, a peptide-solid surface interface, which are binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion.
Arch Biopartners Inc. Fundamentals Summary
| ARCH fundamental statistics | |
|---|---|
| Market cap | CA$124.19m |
| Earnings (TTM) | -CA$3.92m |
| Revenue (TTM) | CA$2.12m |
58.7x
P/S Ratio-31.8x
P/E RatioIs ARCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCH income statement (TTM) | |
|---|---|
| Revenue | CA$2.12m |
| Cost of Revenue | CA$3.78m |
| Gross Profit | -CA$1.66m |
| Other Expenses | CA$2.26m |
| Earnings | -CA$3.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | -78.05% |
| Net Profit Margin | -184.76% |
| Debt/Equity Ratio | -63.7% |
How did ARCH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 23:09 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arch Biopartners Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chelsea Stellick | iA Capital Markets |
| Rahul Sarugaser | Raymond James Ltd. |